Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional UpdatesBusiness Wire • 01/07/24
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/02/24
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D DayBusiness Wire • 12/13/23
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular RiskBusiness Wire • 11/11/23
Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a BetZacks Investment Research • 11/08/23
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration RevenuesZacks Investment Research • 11/03/23
Alnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/02/23
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period ActivityBusiness Wire • 11/02/23
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive YearBusiness Wire • 10/26/23
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of MedicineBusiness Wire • 10/25/23
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer's Disease and Cerebral Amyloid AngiopathyBusiness Wire • 10/25/23
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/19/23
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial ResultsBusiness Wire • 10/19/23
Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable OneSeeking Alpha • 10/10/23